- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02103062
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
10. April 2020 aktualisiert von: Celgene
A SINGLE ARM PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF Nab®-PACLITAXEL, IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER
The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer.
Subjects will be placed into two separate cohorts based on their RAS mutation status.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
ABI-007-COLO-001 is a Phase 2, single arm, open label, multicenter study to evaluate the efficacy and safety of Abraxane (nab-paclitaxel) given on days 1, 8 and 15 of a 28 day cycle in subjects with previously treated metastatic colorectal cancer.
Subjects will be enrolled into cohorts by RAS mutation status (wildtype or mutated).
Stage 1 in a given cohort will enroll 15 subjects in the Intention to Treat population and if more than 8 subjects have Progression Free Survival at the 8 week assessment, then Stage 2 will open in the respective cohort.
Stage 2 will enroll an additional 28 subjects for a total of 43 subjects in each cohort.
The study will be positive if more than 26 subjects with Progression Free Survival at the 8 week assessment are observed in 43 subjects per cohort.
Interim analysis after Stage 1 did not meet protocol defined criteria to proceed to Stage 2. Patients currently enrolled will be followed for Progression Free Survival and until 28 days after last dose, secondary endpoints including overall survival will not be followed
Studientyp
Interventionell
Einschreibung (Tatsächlich)
41
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Lille 59, Frankreich, 59020
- Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique
-
Montpellier cedex 5, Frankreich, 34298
- Centre Regional de Lutte contre le Cancer Val d'Aurelle
-
Saint Herblain 44, Frankreich, 44805
- CRLCC Centre Rene Gauducheau
-
Saint-Cloud, Frankreich, 92210
- Institut Curie
-
Vandoeuvre-Les-Nancy, Frankreich, 54511
- Centre Alexis Vautrin
-
Villejuif, Frankreich, 94805
- Institut Gustave Roussy Hematologie
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria: - 1. Subject is ≥ 18 years old at the time of signing the Informed Consent Form 2. Subject has histological or cytological diagnosis of adenocarcinoma of the colon or rectum, with evidence of metastasis 3. Subject has a known KRAS mutation status (mutated or wild-type).
NRAS mutation status may be unknown.
4. Subject has documented disease progression ≤ 2 months after the last administration of the last standard therapy.
a. Subjects treated with oxaliplatin in the adjuvant setting, should have progressed during or within 6 months of completion of adjuvant therapy 5. Subject has either received prior treatment or was not a candidate for prior treatment, with fluoropyrimidine, oxaliplatin, irinotecan and an anti-VEGF therapy (e.g.
bevacizumab or ziv-aflibercept); and if RAS wild-type tumors, an anti-EGFR therapy (e.g.
cetuximab or panitumumab).
6. Subject has Eastern Cooperative Oncology Group performance status 0 or 1 7. Subject has radiographically-documented measurable disease, as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria 8. Subject has adequate organ functions, evidenced by the following: a. Aspartate Aminotransferase (SGOT), Alanine Transaminase (SGPT) ≤ 2.5 × upper limit of normal range, or < 5 x upper limit of normal range if liver metastasis present b.
Total bilirubin ≤ 1.5 × upper limit of normal range c.
Creatinine ≤ 1.5 × upper limit of normal range 9. Subject has adequate bone marrow function, evidenced by the following: a. Absolute neutrophil count ≥ 1.5 × 109 cells/millimeters3 b.
Platelets ≥ 100 × 109 cells/millimeters3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample) c.
Hemoglobin ≥ 9 grams/decilitre (transfusion is permitted to fulfill this criterion) 10.
Females of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must: a.
Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting Investigational Product therapy (including dose interruptions), and for 3 months following the last dose of Investigational Product; and b.
Have a negative serum pregnancy test (β -human Chorionic Gonadotrophin) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy.
This applies even if the subject practices true abstinence* from heterosexual contact.
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject.
Note: Periodic abstinence (e.g, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
11.
Male subjects must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following Investigational Product discontinuation, even if he has undergone a successful vasectomy.
12. Subject must understand and voluntarily sign an Informed Consent Form prior to any study related assessments or procedures being conducted.
13.
Subject must be able to adhere to the study visit schedule and other protocol requirements.
Exclusion Criteria: - 1. Subject has current or a history of brain metastasis.
In subjects who are symptomatic, a brain scan is required to exclude metastasis.
2. Subject has ≥ National Cancer Institute Common Terminology Criteria for Adverse Events grade 2 peripheral neuropathy at screening 3. Subject has had prior treatment with regorafenib 4. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting Investigational Product, and/or from whom ≥ 30% of the bone marrow was irradiated.
Radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
5. Subject has had major surgery within 14 days prior to starting Investigational Product or has not recovered from postoperative complications 6. Subject has not recovered from the acute toxic effects of prior anticancer therapy, radiation or major /significant trauma 7. Subject has a history of allergy or hypersensitivity to nab-paclitaxel or any of the excipients 8. Subject has a known history of the following within 6 months prior to enrollment (the decision to include the subject in the study): a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or Electrocardiogram abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder 9. Subject has a known infection with hepatitis B or C, or history of human immunodeficiency virus infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications 10.
Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment 11.
Subject has any other malignancy within 5 years prior to enrolment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment) 12. Subject has a history of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa) 13.
Subject has a history of interstitial lung disease , history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies 14.
Subject has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate subject participation in the clinical study (e.g.
chronic pancreatitis, chronic active hepatitis, etc.) 15.
Subject is enrolled in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures 16.
Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study 17.
Subject has any condition that confounds the ability to interpret data from the study 18.
Subject is unwilling or unable to comply with study procedures 19.
Subject is a pregnant or nursing female
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Abraxane (nab®paclitaxel)
Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
|
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression Free Survival (PFS) Rate as Measured at Week 8
Zeitfenster: At week 8 assessment period; up to 56 days
|
PFS rate was measured by Investigator Assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 from the start of study treatment to disease progression or death from any cause, whichever occurred first.
|
At week 8 assessment period; up to 56 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)
Zeitfenster: At week 8 and later; up to day 241
|
DCR was defined as the combined incidence of stable disease confirmed CR or PR and stable disease (SD) measured at the Week 8 assessment or later.
|
At week 8 and later; up to day 241
|
Overall Survival
Zeitfenster: Up to 241 days
|
Overall Survival was the time from the first dose of study drug to patient death from any cause.
|
Up to 241 days
|
Overall Response Rate (ORR)
Zeitfenster: Up to 241 days
|
ORR was defined as the combined incidence of Complete Response (CR) and Partial Response (PR), confirmed no less than 4 weeks after the criteria for response were first met based on RECIST 1.1.
Tumor responses were assessed every 2 cycles using RECIST 1.1 and defined as: • Complete response-disappearance of all target lesions • Partial response- At least a 30% decrease in the sum of diameters of target lesions from baseline • Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD) • Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.
|
Up to 241 days
|
Duration of Response (DOR)
Zeitfenster: Up to 241 days
|
Duration of response was defined as the time from the first tumor assessment when the confirmed CR/PR response criterion was met to the date of disease progression based on investigational assessment following RECIST 1.1.
|
Up to 241 days
|
Number of Participants With Adverse Events
Zeitfenster: Time of the first dose of study treatment to 28 days after the last dose of study drug; maximum treatment duration was 24 weeks
|
A treatment emergent adverse events (TEAE) was defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.
A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.
Safety and Severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Lifethreatening; Grade 5-Fatal;
|
Time of the first dose of study treatment to 28 days after the last dose of study drug; maximum treatment duration was 24 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Kaplan Meier Estimate of PFS by Investigator Assessment
Zeitfenster: Up to 241 days
|
PFS was measured as time from the date of first dose to the date of disease progression according to RECIST 1.1 or death from any cause, whichever was earlier.
|
Up to 241 days
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
5. Mai 2014
Primärer Abschluss (Tatsächlich)
10. November 2014
Studienabschluss (Tatsächlich)
9. Januar 2015
Studienanmeldedaten
Zuerst eingereicht
31. März 2014
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
31. März 2014
Zuerst gepostet (Schätzen)
3. April 2014
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
21. April 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
10. April 2020
Zuletzt verifiziert
1. April 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen
- Neubildungen nach Standort
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Darmerkrankungen
- Darmerkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Kolorektale Neubildungen
- Antineoplastische Mittel
- Albumingebundenes Paclitaxel
Andere Studien-ID-Nummern
- ABI-007-COLO-001
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Kolorektale Neubildungen
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada
Klinische Studien zur ABI-007
-
CelgeneZurückgezogenSolider KrebsVereinigte Staaten
-
National Research Council, SpainHospital Universitario 12 de OctubreAbgeschlossen
-
CelgeneAbgeschlossenBauchspeicheldrüsenkrebsVereinigte Staaten, Kanada, Spanien, Australien, Frankreich, Deutschland, Österreich, Italien, Ukraine
-
CelgeneAbgeschlossenMelanom | MetastasenVereinigte Staaten
-
Celgene CorporationAbgeschlossenNeoplasien der Brust | Metastasen, NeoplasmenVereinigte Staaten
-
Celgene CorporationAbgeschlossenNeubildungen | Metastasen, NeoplasmenVereinigte Staaten
-
Taiho Pharmaceutical Co., Ltd.Abgeschlossen
-
Celgene CorporationAbgeschlossenNeoplasien der Brust | Metastasen, NeoplasmenVereinigte Staaten
-
University Health Network, TorontoCelgene CorporationAbgeschlossen
-
Celgene CorporationAbgeschlossenNicht-kleinzelligem LungenkrebsVereinigte Staaten